erenumab (aimovig) is the first of four new migraine drugs in the pipeline that target calcitonin gene-related peptide (cgrp), a molecule that's produced in nerve cells of the . .
you have successfully subscribed to the breaking news email.
treatment delays are also causing needless anxiety and distress to patients as well as putting lives at serious risk. . .